PL395470A1 - Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego - Google Patents

Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Info

Publication number
PL395470A1
PL395470A1 PL395470A PL39547011A PL395470A1 PL 395470 A1 PL395470 A1 PL 395470A1 PL 395470 A PL395470 A PL 395470A PL 39547011 A PL39547011 A PL 39547011A PL 395470 A1 PL395470 A1 PL 395470A1
Authority
PL
Poland
Prior art keywords
diseases
treatment
nervous system
central nervous
sulfonamide derivatives
Prior art date
Application number
PL395470A
Other languages
English (en)
Inventor
Marcin Kolaczkowski
Monika Jagodzińska
Adam Bucki
Maciej Pawłowski
Andrzej Krukowski
Rafał Rusiecki
Agata Siwek
Małgorzata Wolak
Original Assignee
Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL395470A priority Critical patent/PL395470A1/pl
Priority to BR112013030813A priority patent/BR112013030813A2/pt
Priority to KR1020137035090A priority patent/KR20140041619A/ko
Priority to AU2012277364A priority patent/AU2012277364A1/en
Priority to PCT/IB2012/053318 priority patent/WO2013001505A2/en
Priority to US14/127,435 priority patent/US20140135310A1/en
Priority to EP12762391.6A priority patent/EP2726476A2/en
Priority to JP2014518041A priority patent/JP2014518258A/ja
Priority to CN201280031809.XA priority patent/CN103649077A/zh
Priority to EA201490179A priority patent/EA201490179A1/ru
Priority to CA2838321A priority patent/CA2838321A1/en
Priority to MX2013014662A priority patent/MX2013014662A/es
Publication of PL395470A1 publication Critical patent/PL395470A1/pl
Priority to ZA2014/00636A priority patent/ZA201400636B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL395470A 2011-06-29 2011-06-29 Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego PL395470A1 (pl)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PL395470A PL395470A1 (pl) 2011-06-29 2011-06-29 Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
US14/127,435 US20140135310A1 (en) 2011-06-29 2012-06-29 Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
KR1020137035090A KR20140041619A (ko) 2011-06-29 2012-06-29 중추 신경계 질환의 치료를 위한 지환식 아민의 술폰아미드 유도체
AU2012277364A AU2012277364A1 (en) 2011-06-29 2012-06-29 Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
PCT/IB2012/053318 WO2013001505A2 (en) 2011-06-29 2012-06-29 Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
BR112013030813A BR112013030813A2 (pt) 2011-06-29 2012-06-29 derivados de sulfonamida de aminas alicíclicas para tratamento das doenças do snc
EP12762391.6A EP2726476A2 (en) 2011-06-29 2012-06-29 Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
JP2014518041A JP2014518258A (ja) 2011-06-29 2012-06-29 中枢神経系の疾患の処置のための脂環式アミンのスルホンアミド誘導体
CN201280031809.XA CN103649077A (zh) 2011-06-29 2012-06-29 用于治疗中枢神经系统疾病的脂环族胺类的磺酰胺衍生物
EA201490179A EA201490179A1 (ru) 2011-06-29 2012-06-29 Сульфамидные производные алициклических аминов для лечения заболеваний центральной нервной системы
CA2838321A CA2838321A1 (en) 2011-06-29 2012-06-29 Sulphonamide derivatives of alicyclic amines for the treatment of the central nervous system diseases
MX2013014662A MX2013014662A (es) 2011-06-29 2012-06-29 Derivados de sulfonamida de aminas aliciclicas para el tratamiento de enfermedades del sistema nervioso central.
ZA2014/00636A ZA201400636B (en) 2011-06-29 2014-01-27 Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL395470A PL395470A1 (pl) 2011-06-29 2011-06-29 Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Publications (1)

Publication Number Publication Date
PL395470A1 true PL395470A1 (pl) 2013-01-07

Family

ID=46889381

Family Applications (1)

Application Number Title Priority Date Filing Date
PL395470A PL395470A1 (pl) 2011-06-29 2011-06-29 Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Country Status (13)

Country Link
US (1) US20140135310A1 (pl)
EP (1) EP2726476A2 (pl)
JP (1) JP2014518258A (pl)
KR (1) KR20140041619A (pl)
CN (1) CN103649077A (pl)
AU (1) AU2012277364A1 (pl)
BR (1) BR112013030813A2 (pl)
CA (1) CA2838321A1 (pl)
EA (1) EA201490179A1 (pl)
MX (1) MX2013014662A (pl)
PL (1) PL395470A1 (pl)
WO (1) WO2013001505A2 (pl)
ZA (1) ZA201400636B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
EP3260452A1 (en) * 2016-06-24 2017-12-27 Neurolixis Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
CN106279136B (zh) 2016-08-15 2019-06-21 中山大学 治疗中枢神经系统退行性疾病或脑肿瘤的化合物及其应用
CN116283769B (zh) * 2023-02-10 2025-03-25 绍兴市上虞区武汉理工大学高等研究院 一种环丁烷骈合吡啶磺酰胺类化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482099A (en) 1974-12-11 1977-08-03 Wyeth John & Brother Ltd Sulphonamido derivatives
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
GB9627006D0 (en) 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
WO2001024786A1 (en) 1999-05-13 2001-04-12 Shionogi & Co., Ltd. Preventive or therapeutic drugs for diabetes
WO2001007436A2 (en) 1999-07-28 2001-02-01 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
FR2804429B1 (fr) 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
WO2005068461A1 (en) * 2004-01-07 2005-07-28 Aryx Therapeutics Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CN1918157B (zh) * 2004-01-07 2010-06-23 ARYx医疗有限公司 立体异构化合物及治疗胃肠道和中枢神经系统紊乱的方法
AU2005212835A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted Azetidine compounds, their preparation and use as medicaments
ES2244314B1 (es) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos.
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
CN101421234A (zh) * 2006-04-19 2009-04-29 艾博特股份有限两合公司 适于治疗对5-羟色胺5ht6受体调节有反应的病症的杂环芳基砜
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
KR101152659B1 (ko) * 2009-10-09 2012-06-15 한국과학기술연구원 세로토닌 수용체 길항 작용과 세로토닌 트랜스포터 억제 작용을 동시에 가지는 설폰아마이드 화합물

Also Published As

Publication number Publication date
BR112013030813A2 (pt) 2016-12-06
WO2013001505A3 (en) 2013-03-07
EP2726476A2 (en) 2014-05-07
WO2013001505A2 (en) 2013-01-03
MX2013014662A (es) 2014-03-27
CN103649077A (zh) 2014-03-19
CA2838321A1 (en) 2013-01-03
JP2014518258A (ja) 2014-07-28
EA201490179A1 (ru) 2014-04-30
US20140135310A1 (en) 2014-05-15
ZA201400636B (en) 2014-11-26
AU2012277364A1 (en) 2014-01-23
KR20140041619A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
ZA201404787B (en) Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases
IL221517A (en) A device for treating headaches
EP2788020A4 (en) THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
ZA201309557B (en) Methods of treatment for retinal diseases
IL225668A (en) Formulations for the treatment of disorders of the upper respiratory tract
IL225438A0 (en) Use of active pharmaceutical compounds to treat disorders of the central nervous system
IL230960A0 (en) A device for the treatment of eye disease
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
IL230959B (en) A device for the treatment of eye disease
ZA201309554B (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
PL2790712T3 (pl) Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego
PT2691103T (pt) Método para o tratamento de distúrbios da pele
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
IL239273A0 (en) A method of treating diseases
ZA201400636B (en) Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
ZA201407506B (en) Sulphonamide derivatives of benzylamine for the treatment of cns diseases
IL229791A0 (en) Indoleamine derivatives for the treatment of diseases of the central nervous system
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK40043513B (en) Interval therapy for the treatment of eye diseases
LT2704747T (lt) Akių lašai, skirti konjuktivochalazės gydymui
IL228973A (en) Oxymetazoline for the treatment of rectal disorders
HK1193343A (en) Methods for treating diseases of the retina
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
GB201101183D0 (en) Treatment of neurodegenerative disorders